Liothyronine (T3) vs Semaglutide
FDA Approved vs FDA Approved
monitor Mechanism-based · 50% Both Liothyronine (T3) and Semaglutide promote fat breakdown. While additive fat loss is possible, excessive lipolysis can cause rapid free fatty acid elevation and cardiac strain. Monitor heart rate and adjust doses gradually.
Molecular Data
Liothyronine (T3) Semaglutide
Weight 650.97 Da 4,113.64 Da
Half-life ~1 day ~7 days (168 hours)
Chain — 31 amino acids
Type Thyroid hormone (C15H12I3NO4) GLP-1 receptor agonist
Key Benefits
Liothyronine (T3)
01 Direct and rapid increase in basal metabolic rate
02 Enhanced fat oxidation and lipolysis
03 Improved energy levels and reduction of hypothyroid fatigue
04 Faster-acting than T4 with effects noticeable within hours to days
05 Useful when peripheral T4-to-T3 conversion is impaired (illness, caloric deficit, stress)
06 Supports body temperature regulation and thermogenesis
07 Can improve cognitive clarity and reduce brain fog associated with low thyroid function
Semaglutide
01 15-20% average body weight reduction
02 Established cardiovascular protection
03 Convenient once-weekly dosing options
04 Comprehensive safety data from extensive trials
05 Flexible injectable and oral formulations
Dosing Protocols
Liothyronine (T3)
25-75 mcg/day (replacement) / 1-2x daily (oral)
Semaglutide
0.25mg starting, titrate to 1-2.4mg weekly / Once weekly (same day each week)
Weight Loss Initiation 0.25mg Weekly x 4 weeks, then increase
Weight Loss Maintenance 2.4mg Weekly (after 16-week titration)
Diabetes Management 0.5-1mg Weekly
Cardiovascular Protection 0.5-1mg Weekly
Tolerability-Based 0.25-2.4mg Weekly (individualized)
Side Effects
Liothyronine (T3)
Tachycardia and palpitations (increased heart rate, especially at higher doses)
Anxiety, nervousness, and irritability
Insomnia and disrupted sleep architecture
Increased sweating and heat intolerance
Tremor (fine hand tremor, similar to hyperthyroid presentation)
Increased appetite despite accelerated metabolism
Loose stools or increased bowel frequency
Semaglutide
Nausea
Diarrhea
Vomiting
Constipation
Abdominal pain
Contraindications
Untreated adrenal insufficiency (must correct cortisol deficiency before starting T3)
Acute myocardial infarction or unstable angina
Thyrotoxicosis or untreated hyperthyroidism
Known hypersensitivity to liothyronine or any tablet excipients
Uncorrected adrenal cortical insufficiency (risk of adrenal crisis)
Personal or family history of medullary thyroid cancer
Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Liothyronine (T3) Semaglutide
Status FDA Approved FDA Approved
References 5 studies 9 studies
Latest September 2023 2025-06
FDA Approved Yes Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.